CO5150205A1 - METHODS OF INCREASING THE OSEO VOLUME THAT INCLUDES MANAGING AN SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENT - Google Patents

METHODS OF INCREASING THE OSEO VOLUME THAT INCLUDES MANAGING AN SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENT

Info

Publication number
CO5150205A1
CO5150205A1 CO00016009A CO00016009A CO5150205A1 CO 5150205 A1 CO5150205 A1 CO 5150205A1 CO 00016009 A CO00016009 A CO 00016009A CO 00016009 A CO00016009 A CO 00016009A CO 5150205 A1 CO5150205 A1 CO 5150205A1
Authority
CO
Colombia
Prior art keywords
agonist
selective
treatment
subject
requires
Prior art date
Application number
CO00016009A
Other languages
Spanish (es)
Inventor
James Richard Hartke
Mark Walden Lundy
Mitchell Anthony Delong
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of CO5150205A1 publication Critical patent/CO5150205A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a nuevos métodos de aumentar el volumen óseo que comprenden administrar un agonista EP1 selectivo que no ocurre naturalmente a un sujeto que requiere de tal tratamiento.Esta invención se refiere adicionalmente a un método para tratar o prevenir trastornos óseos que comprende administrar un agonista EP1 selectivo que no ocurre naturalmente a un sujeto que requiere tal tratamiento.<EMI FILE="00016009_1" ID="1" IMF=JPEG >The present invention relates to new methods of increasing bone volume comprising administering a selective EP1 agonist that does not occur naturally to a subject requiring such treatment.This invention further relates to a method for treating or preventing bone disorders comprising administering a selective EP1 agonist that does not naturally occur to a subject that requires such treatment. <EMI FILE = "00016009_1" ID = "1" MFI = JPEG>

CO00016009A 1999-03-05 2000-03-06 METHODS OF INCREASING THE OSEO VOLUME THAT INCLUDES MANAGING AN SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENT CO5150205A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12306399P 1999-03-05 1999-03-05

Publications (1)

Publication Number Publication Date
CO5150205A1 true CO5150205A1 (en) 2002-04-29

Family

ID=22406507

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00016009A CO5150205A1 (en) 1999-03-05 2000-03-06 METHODS OF INCREASING THE OSEO VOLUME THAT INCLUDES MANAGING AN SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENT

Country Status (10)

Country Link
EP (1) EP1158969A2 (en)
JP (1) JP2002538105A (en)
AU (1) AU3711900A (en)
CA (1) CA2366755A1 (en)
CO (1) CO5150205A1 (en)
IL (1) IL145128A0 (en)
NO (1) NO20014192L (en)
NZ (1) NZ513828A (en)
PE (1) PE20001552A1 (en)
WO (1) WO2000051585A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006118173A1 (en) 2005-04-28 2008-12-18 小野薬品工業株式会社 Transdermal absorption preparation
US8410171B2 (en) 2006-10-26 2013-04-02 Ono Pharmaceutical Co., Ltd. Adhesive preparation
WO2009133863A1 (en) 2008-04-28 2009-11-05 国立大学法人浜松医科大学 Immunopotentiating agent comprising ep1 agonist
WO2011109729A2 (en) * 2010-03-05 2011-09-09 University Of Rochester Ep1 inhibition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3982016A (en) * 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
AU2146592A (en) * 1991-05-29 1993-01-08 Sepracor, Inc. Combination of nsaids and prostaglandins and uses therefor
BR9811780A (en) * 1997-09-09 2000-09-12 Procter & Gamble Bone volume increase method using non-naturally occurring selective fp agonists
CA2346031A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation
WO2000051616A1 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives

Also Published As

Publication number Publication date
NO20014192D0 (en) 2001-08-29
JP2002538105A (en) 2002-11-12
NZ513828A (en) 2001-09-28
WO2000051585A3 (en) 2001-01-25
WO2000051585A2 (en) 2000-09-08
PE20001552A1 (en) 2001-01-30
NO20014192L (en) 2001-11-05
AU3711900A (en) 2000-09-21
CA2366755A1 (en) 2000-09-08
EP1158969A2 (en) 2001-12-05
IL145128A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
AU4935701A (en) Use of insulin for the treatment of cartilagenous disorders
BR9811780A (en) Bone volume increase method using non-naturally occurring selective fp agonists
IS1724B (en) METHOD OF TREATING METAL TRANSPORTATION
CO5221115A1 (en) NEW FUNGICIDE COMPOUNDS
EP1205154A3 (en) Osteosynthesis plating apparatus and method with extension plate
BR0312785A (en) Treatment of Tnf-related disorders (alpha)
NO972043L (en) Tienopyridine or thienopyrimidine derivatives and their use
WO2004032988A3 (en) Coupling agents for orthopedic biomaterials
BR0114758A (en) Ep4 receptor inhibitors for rheumatoid arthritis treatment
WO2001030264A3 (en) Ankle replacement system
BR0115696A (en) Use of bisphosphonates for pain management
CO5271724A1 (en) USE OF PROSTAGLANDIN AGONISTS TO TREAT ERECTILE DYSFUNCTION OR IMPOTENCE
IL162616A0 (en) Tetrahydroquinoline analogues as muscarinic agonists
BR9913705A (en) Methods for the treatment of multiple myeloma and bone tissue resorption induced by myeloma using integrin antagonists
EP1173470A4 (en) Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
CO5150205A1 (en) METHODS OF INCREASING THE OSEO VOLUME THAT INCLUDES MANAGING AN SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENT
EP1254260A4 (en) Methods for diagnosing and treating heart disease
CO5150178A1 (en) ELETRIPTAN MONOHIDRATE BROMOHYDRATE AND PROCEDURE FOR PREPARATION
CO5280195A1 (en) SYNTHETIC COMBINATIONS OF AN NK RECEIVER ANTAGONIST, AND A GABA STRUCTURAL ANALALOG
HK1053053A1 (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies.
GB2331301C (en) Galanin
AU2003301744A1 (en) Fracture pin
WO2000012047A3 (en) Enhancement of return to independent living status with a growth hormone secretagogue
Moroni et al. Fixation strength of tapered versus bicylindrical hydroxyapatite‐coated external fixation pins: An animal study
PT1152757E (en) MMP INHIBITORS IN CONJUNCTIVE TISSUE GROUNDING